Q-omics provides the consensus-scored TMEM191C profile across patient tissues and cancer cell-line models. TMEM191C expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM191C is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TMEM191C RNA expression shows 17,036 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TMEM191C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM191C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM191C survival associations across molecular data types. TMEM191C RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM191C RNA expression–survival associations across cancer types. High TMEM191C expression shows unfavorable associations in ACC, UVM, COAD, KICH and LIHC, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM191C RNA expression.
This table summarizes TMEM191C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM191C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM191C shows higher tumor expression in KIRC, KICH, LIHC, BRCA, LUSC and HNSC. The KIRC box plot shows higher TMEM191C RNA expression in tumor versus normal tissue (log2 FC = +0.098, t-test p < 0.001).
This table shows molecular features associated with TMEM191C in patient tissues and cancer cell lines. In patient samples, TMEM191C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM191C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
